Gossamer Bio Inc   (GOSS)
Other Ticker:  
Price: $0.7466 $-0.03 -3.290%
Day's High: $0.792 Week Perf: -10.92 %
Day's Low: $ 0.71 30 Day Perf: 48.43 %
Volume (M): 7,355 52 Wk High: $ 9.55
Volume (M$): $ 5,491 52 Wk Avg: $1.50
Open: $0.78 52 Wk Low: $0.45

 Market Capitalization (Millions $) 144
 Shares Outstanding (Millions) 193
 Employees 62
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -187
 Cash Flow (TTM) (Millions $) -71
 Capital Exp. (TTM) (Millions $) 0

Gossamer Bio Inc
Gossamer Bio Inc. is a biopharmaceutical company that focuses on discovering, developing and commercializing therapeutics that address unmet needs in the treatment of various infectious, inflammatory and oncology diseases. It was founded in 2015 by Dr. Faheem Hasnain and Dr. Sheila Gujrathi, both of whom have extensive experience in the pharmaceutical industry and have previously worked together at Receptos, a biopharmaceutical company that was acquired by Celgene in 201

The company is headquartered in San Diego, California, and has a robust pipeline of candidates for various indications. Gossamer Bio has a strong focus on cutting-edge technology and market research to stay ahead of the competition. It has developed and acquired intellectual property rights in various small molecule drugs, proteins, and therapeutics.

Gossamer Bio's pipeline includes candidates that target Type 2 inflammation, COVID-19, and multiple oncology programs. Its lead product candidate, GB001, is a small molecule antagonist of the prostaglandin D2 receptor 2 (DP2) designed to treat eosinophilic asthma and chronic rhinosinusitis with nasal polyps. The company is also developing GB002, an inhaled inhibitor of IL-9, for the treatment of asthma, as well as biologic programs that target Type 2 inflammation.

In response to the COVID-19 pandemic, Gossamer Bio has developed GB004, an antibody drug designed to prevent and treat severe COVID-19 infections. It is a SARS-CoV-2-neutralizing antibody that has been shown to have potent in vitro neutralizing activity against multiple variants of the virus. The company is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of GB004 as a treatment for COVID-19.

In the oncology space, Gossamer Bio is developing GB1275, an oral CD11b agonist inhibitor that is designed to treat a wide range of solid tumors. GB1275 is currently being tested in Phase 2 clinical trials for various indications. The company is also developing GB2064, a first-in-class oral hypoxia-inducible factor (HIF) inhibitor that is designed to treat a wide range of solid tumors.

In addition to its clinical programs, Gossamer Bio has initiated preclinical research on multiple other programs, including candidates for the treatment of chronic obstructive pulmonary disease, fibrotic disorders, and various oncology programs.

Gossamer Bio has established collaborations with various academic institutions, pharmaceutical companies, and research organizations to further advance its pipeline candidates. The company has secured several rounds of funding from both institutional investors and venture capitalists and has a strong financial position to support its ongoing operations.

In summary, Gossamer Bio Inc. is a biopharmaceutical company that is focused on discovering and developing innovative therapeutics that treat a wide range of infectious, inflammatory, and oncology diseases. With a robust pipeline of candidates and a strong foundation of scientific and technological expertise, Gossamer Bio is poised to emerge as a leading player in the biopharmaceutical industry.

   Company Address: 3013 Science Park Road San Diego 92121 CA
   Company Phone Number: 684-1300   Stock Exchange / Ticker: NASDAQ GOSS
   GOSS is expected to report next financial results on March 16, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com